NIAID

MicroQuin Enters Agreement with NIAID to Evaluate MicroQuin Therapeutics for the treatment of viral infections

Retrieved on: 
화요일, 8월 24, 2021
Scientific research on the International Space Station, NIAID, Degenerative disease, Center, Virus, Therapy, Severe acute respiratory syndrome coronavirus 2, Respiratory syncytial virus, Research, Food, MQP, CASIS, International Space Station, National Institute of Allergy and Infectious Diseases, RSV, Patient, Infection, National Institute, NCEA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Vaccine

The company's viral infection program has shown positive results in vitro with viral inhibition ranging from 75-99.5% depending on the virus.

Key Points: 
  • The company's viral infection program has shown positive results in vitro with viral inhibition ranging from 75-99.5% depending on the virus.
  • "We are pleased to announce this agreement with NIAID to provide further evaluation of our MQPs, which have shown broad anti-viral activity and significant viral inhibition in vitro.
  • MicroQuin hopes to accelerate its anti-viral program to address the world's urgent need for the effective treatment of a range of viral infections.
  • The company's viral infection program results have outshone current influenza vaccine effectiveness with viral inhibition of up to 99.5% in vitro.

BlueWillow Biologics Announces Positive Interim Results from Phase 1 Trial of Intranasal Anthrax Vaccine

Retrieved on: 
화요일, 8월 24, 2021
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Public Health England, NIAID, Nasal mucosa, Program, Anthrax, Immune system, Social work, HSV, Antigen, RPA, National, National Institute of Allergy and Infectious Diseases, Food, RSV, Public health, Mortality, Vertically transmitted infection, Risk, Immunity, Urinary tract infection, Vaccine, CEO, Infection, NIH, Vaccination, PBL, Department of Health and Social Care, National Institute, COVID-19, Department, MD

BlueWillow Biologics, Inc. , a privately held clinical-stage biopharmaceutical company developing intranasal vaccines, today announced positive interim results from the Phase 1 clinical trial of BW-1010, its next-generation intranasal anthrax vaccine candidate.

Key Points: 
  • BlueWillow Biologics, Inc. , a privately held clinical-stage biopharmaceutical company developing intranasal vaccines, today announced positive interim results from the Phase 1 clinical trial of BW-1010, its next-generation intranasal anthrax vaccine candidate.
  • The interim data showed that vaccine administered intranasally as two doses 4 weeks apart was safe and well tolerated.
  • Were thankful for the commitment of our colleagues at PBL and NIAIDs support for the Phase 1 trial.
  • We look forward to reporting complete results when the trial concludes this fall and advancing the anthrax vaccine through further clinical trials.

Everbridge Wins 2021 Service to the CitizenTM Award for Industry-Leading Return to Work and Vaccine Distribution Solutions Deployed by State and Local Governments Across the U.S.

Retrieved on: 
월요일, 8월 23, 2021
Public Policy, Government, Security, Technology, Other Policy Issues, Other Technology, Mobile, Wireless, Software, People, Service, Government, Privacy, SEC, Muscogee (Creek) Nation, Virgin Group, Battery Ventures, Health, Intellectual property, Safety, Risk, Infection, Department, Creek, Weather, NIAID, Organization, Walter Szczerbiak, Everbridge, Communication, Forward-looking statement, Shield, Willard, CEO, CNN, State, National Institute, Apollo Global Management, Technology, NASDAQ, Citizenship, FDA, Certification, Growth, City, Emergency, Private Securities Litigation Reform Act, Population density, Multimedia, CEM, Commissioner of Food and Drugs, NIH, Annual report, COVID-19, Pharmaceutical industry, Risk management

Award winners will be recognized at the Willard InterContinental in Washington, D.C. on September 22, 2021.

Key Points: 
  • Award winners will be recognized at the Willard InterContinental in Washington, D.C. on September 22, 2021.
  • There are heroes across the government that work tirelessly to provide the best services possible under sometimes difficult circumstances.
  • In May 2020, Everbridge launched its Return to Work software solutions to help governments and enterprises improve safety for citizens and employees as they integrate back to public spaces.
  • In addition, the Everbridge CEM platform proved instrumental to the deployment of vaccine scheduling systems by government agencies.

Texas State Elected Officials Received Notice of Pandemic Criminal Conspiracy and Racketeering

Retrieved on: 
목요일, 8월 19, 2021
Hysteria, University, NIAID, Chapel Hill, District of Columbia Voting Rights Amendment, EcoHealth Alliance, Public Readiness and Emergency Preparedness Act, New Normal, Population, Tenth, Federation, National Institutes of Health, CDC, Physician, University of North Carolina at Pembroke, Constitution, Interview, Research, World Health Organization, Economics, Travel, Person, Doctor of Philosophy, Texas Senators, GOAL, DSHS, Fear, World, National Childhood Vaccine Injury Act, EUA, Health, National academy, Emergency, Intimidation, SCR, Goal, Compliance, Immunity, Vaccine, CEO, SARS, NIH, FDA, COVID-19, Department, National Institute, Pharmaceutical industry

BRADY, Texas, Aug. 19, 2021 /PRNewswire/ -- Beginning August, 9, 2021, Texas Right To Know delivered the Omega Brief to open offices of Texas Representatives, Texas Senators, Governor Greg Abbott, Lt.

Key Points: 
  • BRADY, Texas, Aug. 19, 2021 /PRNewswire/ -- Beginning August, 9, 2021, Texas Right To Know delivered the Omega Brief to open offices of Texas Representatives, Texas Senators, Governor Greg Abbott, Lt.
  • Summarized from the July 11, 2021 interview of David Martin, PhD by Reiner Fuellmich, the Omega Brief suggests that the current pandemic is a criminal conspiracy and racketeering enterprise beginning in 1999.
  • The brief includes Dr. Martin's Fauci/COVID-19 Dossier that outlines eight federal criminal charges from evidence contained in patent records.
  • "TheOmega Brief isaconsolidationofevidence ofcriminal activity providedby national andinternational expertwitnessesrevealingindividuals whoareresponsiblefor thecoronavirus pandemic.

EverGlade Consulting Assists United Safety Technology, Inc. in Securing $97 Million DOD Award

Retrieved on: 
목요일, 8월 19, 2021
ACT, Air force, BARDA, Everglade, NIAID, PPE, Department of Defense Office of Inspector General, Technology, United States Department of Health and Human Services, ASPR, Federation, HHS, Pandemic, Assistant, Acquisition, Multimedia, Families First Coronavirus Response Act, UST, CEO, Department of the Air Force Police, DAF, COVID-19, DOD, Department, DTRA, Personal protective equipment, Pharmaceutical industry

WASHINGTON, Aug. 19, 2021 /PRNewswire/ -- EverGlade Consulting ("EverGlade"), a Washington, D.C. based consulting firm, has successfully aided United Safety Technology, Inc. ("UST") in securing $97 million in DOD funding to increase the domestic production capacity of nitrile gloves.

Key Points: 
  • WASHINGTON, Aug. 19, 2021 /PRNewswire/ -- EverGlade Consulting ("EverGlade"), a Washington, D.C. based consulting firm, has successfully aided United Safety Technology, Inc. ("UST") in securing $97 million in DOD funding to increase the domestic production capacity of nitrile gloves.
  • On June 21, 2021, the Department of Defense (DOD), on behalf of and in coordination with the Department of Health and Human Services (HHS), awarded a $96 million award to United Safety Technology, Inc. to increase the domestic production of nitrile gloves.
  • EverGlade Consulting is a Washington, DC based consulting firm that helps clients navigate the federal landscape.
  • For additional information about EverGlade Consulting, visit: https://www.EverGlade.com
    View original content to download multimedia: https://www.prnewswire.com/news-releases/everglade-consulting-assists-un...

Gritstone and CEPI Announce Agreement to Advance Second-Generation COVID-19 Vaccine Program (CORAL) Against SARS-CoV-2 Variants of Concern

Retrieved on: 
화요일, 8월 17, 2021
Vaccine, Epidemic, National Institute of Allergy and Infectious Diseases, University, NIAID, COVID, Program, SAGE, Faculty, Severe acute respiratory syndrome coronavirus 2, U.S. Securities and Exchange Commission, Infection, Immune system, GLOBE, CEPI, Gilead Sciences, Antigen, COVAX, La Jolla Institute for Immunology, CORAL, University of the Witwatersrand, Outline of health sciences, Cell, HIV, National, Bill & Melinda Gates Foundation, Immunodeficiency, Epitope, Coalition, Clinical trial, RNA transfection, Immunology, SAM, McMaster Faculty of Health Sciences, Volunteering, Coalition for Epidemic Preparedness Innovations, Patient, Solution, CEO, Bill, NIH, Neoplasm, SLATE, COVID-19, National Institute, Convalescence, Security (finance), Pharmaceutical industry

With this unique antigenic breadth, our CORAL vaccine may offer protection against emerging spike variants of SARS-CoV-2 that appear challenging for first generation vaccines, said Andrew Allen, M.D., Ph.D., co-founder, president and chief executive officer of Gritstone.

Key Points: 
  • With this unique antigenic breadth, our CORAL vaccine may offer protection against emerging spike variants of SARS-CoV-2 that appear challenging for first generation vaccines, said Andrew Allen, M.D., Ph.D., co-founder, president and chief executive officer of Gritstone.
  • Under the terms of the agreement, CEPI will fund a multi-arm Phase 1 study evaluating the CORAL programs SAM vaccine in nave, convalescent, and HIV+ patients.
  • Gritstones CORAL program is a second-generation SARS-CoV-2 vaccine platform delivering spike and additional SARS-CoV-2 T cell epitopes, offering the potential for deep, broad, and durable protection against SARS-CoV-2 variants.
  • Additionally, the company has a global collaboration for the development of a therapeutic HIV vaccine with Gilead Sciences.

Lumen Bioscience Teams with Google to Apply Machine Learning to Biologics Manufacturing

Retrieved on: 
수요일, 8월 11, 2021
NIAID, Bill & Melinda Gates Foundation, United States Army Medical Research and Development Command, Machine learning, AI, National Renewable Energy Laboratory, Temperature, Department, News, Melinda Gates, ACCESS, BARDA, National Institute, Use of Free and Open-Source Software (FOSS) in the U.S. Department of Defense, Primary energy, COVID-19, Norovirus, BioRxiv, Infection, U.S. Department of Energy, Office of Inspector General, CHO, National Institute of Allergy and Infectious Diseases, Research, Water, CGMP, PH, Method, Lumen, Rockefeller University, Bill, Photosynthesis, ML, Inflammatory bowel disease, MTEC, Drug development, Protein, Pharmaceutical industry, Fine chemical

The research, led by Caitlin Gamble, Lumen and Drew Bryant at Google Accelerated Science, was funded in part by the Bill & Melinda Gates Foundation.

Key Points: 
  • The research, led by Caitlin Gamble, Lumen and Drew Bryant at Google Accelerated Science, was funded in part by the Bill & Melinda Gates Foundation.
  • Lumen Bioscience simultaneously announced receipt of $2 million in additional grant funding from the Department of Energy to support further development of these research findings.
  • Pending peer-review, the research titled " Machine Learning Optimization of Photosynthetic MicrobeCultivation and Recombinant Protein Production ," has been posted on the online preprint server bioRxiv .
  • Lumen Bioscience discovers, develops, and manufactures biologic drug candidates for several prevalent, worldwide diseasesmany of which currently lack any effective treatments.

Matinas BioPharma Reports Second Quarter 2021 Financial Results and Operational Highlights

Retrieved on: 
화요일, 8월 10, 2021
Private Securities Litigation Reform Act, NIAID, LNC, Investor, CFF, National Institute of Allergy and Infectious Diseases, FDA, Data monitoring committee, Food, Patient, COVID-19, Research, Mycosis, Consultant, Risk, Clinical trial, Infection, Form 10-K, DPA, Cystic fibrosis, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Caco-2, Safety, NTM, Solution, NYSE, Cystic Fibrosis Foundation, DSMB, SEC, RNA transfection, Cohort, Sale, Cryptococcosis, GLOBE, Technology, Therapy, Forward-looking statement, SAD, Partnership, Hand, DNA, Company, Enactment, Degenerative disease, EPA, Vaccine, National Institute, Pharmaceutical industry, Animal

BEDMINSTER, N.J., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of critical therapeutics through its paradigm-changing lipid nanocrystal (LNC) platform delivery technology, today reported financial results for the second quarter ended June 30, 2021, along with a corporate update.

Key Points: 
  • ET
    BEDMINSTER, N.J., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical companyfocused on improving the intracellular delivery of critical therapeutics through its paradigm-changing lipid nanocrystal (LNC) platform delivery technology, today reported financial results for the second quarter ended June 30, 2021, along with a corporate update.
  • The Company expects to initiate a Phase 1 single ascending dose (SAD) pharmacokinetic study of MAT2501 in healthy volunteers in the fourth quarter of 2021.
  • Research and development expenses for the second quarter of 2021 were $2.5 million, compared to $3.4 million for the same period in 2020.
  • General and administrative expenses for the second quarter of 2021 were $2.3 million, essentially unchanged compared to $2.4 million in the same period in 2020.